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Abstract
Background: Betulinic acid (BA) inhibits growth of several cancer cell lines and tumors and the effects of BA have
been attributed to its mitochondriotoxicity and inhibition of multiple pro-oncogenic factors. Previous studies show
that BA induces proteasome-dependent degradation of specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4
in prostate cancer cells and this study focused on the mechanism of action of BA in colon cancer cells.
Methods: The effects of BA on colon cancer cell proliferation and apoptosis and tumor growth in vivo were
determined using standardized assays. The effects of BA on Sp proteins and Sp-regulated gene products were
analyzed by western blots, and real time PCR was used to determine microRNA-27a (miR-27a) and ZBTB10 mRNA
expression.
Results: BA inhibited growth and induced apoptosis in RKO and SW480 colon cancer cells and inhibited tumor
growth in athymic nude mice bearing RKO cells as xenograft. BA also decreased expression of Sp1, Sp3 and Sp4
transcription factors which are overexpressed in colon cancer cells and decreased levels of several Sp-regulated
genes including survivin, vascular endothelial growth factor, p65 sub-unit of NFB, epidermal growth factor receptor,
cyclin D1, and pituitary tumor transforming gene-1. The mechanism of action of BA was dependent on cell context,
since BA induced proteasome-dependent and proteasome-independent downregulation of Sp1, Sp3 and Sp4 in
SW480 and RKO cells, respectively. In RKO cells, the mechanism of BA-induced repression of Sp1, Sp3 and Sp4 was
due to induction of reactive oxygen species (ROS), ROS-mediated repression of microRNA-27a, and induction of the
Sp repressor gene ZBTB10.
Conclusions: These results suggest that the anticancer activity of BA in colon cancer cells is due, in part, to
downregulation of Sp1, Sp3 and Sp4 transcription factors; however, the mechanism of this response is cell context-
dependent.
Background
Colorectal cancer is a leading cause of death in most
developed countries including the United States, and in
2010 it is estimated that over 102,700 new cases will be
diagnosed and 51,370 deaths will occur in the United
States [1]. Genetic susceptibility accounts for 15 - 25% of
colon cancer cases, and genetic markers provide important
insights on factors important for the molecular and
genetic changes that result in development of this disease
[2]. Familial adenomatous polyposis syndromes [3,4], her-
editary non-polyposis colorectal cancer [5-8], and other
polyposis syndromes which increase the incidence of col-
orectal cancer including Peutz Jegher’s syndrome, familial
juvenile polyposis, and hereditary mixed polyposis syn-
drome, are linked to mutations in LKB1, STK11, SMAD4,
PTEN, E-cadherin, cyclin D1, and transforming growth
factor b receptors [2]. * Correspondence: ssafe@cvm.tamu.edu
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variable among different regions of the world and the
changes in incidence of this disease in migrants suggests
that environmental factors related to diet contribute to
development of colon cancer [9,10]. Fruits, nuts and
vegetables contain diverse anticarcinogenic phytochem-
icals; however, epidemiological studies give variable
results with respect to their chemopreventive effects and
similar variability among studies has been reported for
the protective effects of dietary folate [11-14]. Most colon
cancer patients present with localized disease which is
treated with curative surgery; however, disease relapse is
experienced by up to 40% of patients [15-17]. Cytotoxic
drugs are primarily used for colon cancer chemotherapy
and there is a increasing need to develop mechanism-
based drugs for treating this disease.
Specificity protein (Sp) transcription factors Sp1, Sp3
and Sp4 are overexpressed in colon and other cancer cell
lines [18-23], and Sp1 is a negative prognostic factor for
survival of pancreatic and gastric cancer patients [24,25].
The potential importance of Sp transcription factors as
drug targets is due not only to their overexpression in
multiple tumor types but also to their relatively low
expression in non-tumor rodent and human tissues, and
this is consistent with the reported decrease of Sp1
expression with increasing age [26-28]. RNA interference
studies which knockdown Sp1, Sp3 and Sp4 (individually
or combined) have identified several Sp-regulated gene-
products that are themselves individual targets for new
mechanism-based drugs. Sp-regulated genes include sev-
eral that are important for cancer cell proliferation
[cyclin D1, epidermal growth factor receptor (EGFR),
hepatocyte growth factor receptor (c-MET)], survival
(bcl-2 and survivin), angiogenesis [vascular endothelial
growth factor (VEGF) and its receptors (VEGFR1/R2)
and pituitary tumor-transforming gene 1 (PTTG-1)], and
inflammation (p65 subunit of NFB) [23,29-38].
Betulinic acid (BA) is a naturally occurring triterpenoid
which inhibits growth of multiple tumors [39,40]. Studies
in this laboratory show that BA inhibits prostate cancer
cell and tumor (xenograft) growth and this is due, in
part, to proteasome-dependent downregulation of Sp1,
Sp3, Sp4 and several Sp-regulated genes [20]. In this
study, we show that BA inhibits growth of colon cancer
cells and tumors and downregulates Sp transcription fac-
tors through activation of proteasome-dependent
(SW480 cells) and proteasome-independent (RKO cells)
pathways.
Methods
Cell proliferation and cell cycle progression assays
The RKO and SW480 colon cancer cell lines were pre-
viously characterized at the M.D. Anderson Cancer Cen-
ter (Houston, TX) and kindly provided by Dr. Stanley
Hamilton. RKO and SW480 colon cancer cells (2 × 10
4
per well) were plated in 12-well plates and allowed to
attach for 24 h. The medium was then changed to
DMEM/Ham’s F-12 medium containing 2.5% charcoal-
stripped FBS, and either vehicle [dimethyl sulfoxide
(DMSO)] or different concentrations of the compound
were added. Fresh medium and compounds were added
every 48 h, and cells were then trypsinized and counted
after 48 and 96 h using a Coulter Z1 cell counter. Results
are expressed as means ± SE for at least 3 replicate deter-
minations for each treatment group. RKO and SW480
cells were treated with either the vehicle (DMSO) or BA
for 24 h. Cells were trypsinized, centrifuged and resus-
pended in staining solution containing 50 μg/ml propi-
dium iodide, 4 mmol/L sodium citrate, and 30 units/ml
RNase. After incubation at room temperature for 1 h,
cells were analyzed on a FACS Vantage SE DiVa made by
Becton Dickinson, using FACSDiva Software V4.1.1. Pro-
pidium iodide (PI) fluorescence was collected through a
610SP bandpass filter, and list mode data were acquired
on a minimum of 50,000 single cells defined by a dot plot
of PI width vs. PI area. Data analysis was performed in
BD FACSDiva Software V4.1.1 using PI width vs.P Ia r e a
to exclude cell aggregates.
Plasmids, transfection assay and antibodies
Sp1 and Sp3 promoter constructs were kindly provided by
Drs. Carlos Cuidad and Veronique Noe (University of Bar-
celona, Barcelona, Spain). The pVEGF-2068 construct
contains a VEGF promoter insert (positions -2068 to +54)
linked to luciferase reporter gene. The pSurvivin-269 was
kindly provided by Dr. M. Zhou (Emory University,
Atlanta, GA). The PTTG-1-luc construct containing the
-1373 to +3 region of the PTTG-1 promoter was provided
by Dr. Kakar (University of Louisville, Louisville, KY).
Colon cancer cells (1.5 × 10
5) were seeded in 12-well
plates using DMEM:Ham’s F-12 media containing 2.5%
charcoal stripped serum. After 24 h, cells were transfected
with 0.4 μg of reporter gene constructs and 0.04 μgo fb-
Gal using Lipofectamine 2000 according to manufacturer’s
protocol. Reporter lysis buffer and luciferase reagent for
luciferase studies were supplied by Promega (Madison,
WI). Five h after transfection, cells were treated with con-
trol or BA for 22-24 h and luciferase activity (normalized
to b-galactosidase) was determined using Lumicount
luminometer (PerkinElmer Life and Analytical Sciences).
For RNA interference assays with iSp, a mixture of oligo-
nucleotides containing siRNAs against Sp1, Sp3 and Sp4
(combined) was used as previously described [20,21,34].
Antibodies for Sp1, Sp3, Sp4, cyclin D1, EGFR, NFB
(p65), VEGF and VEGFR1 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). c-PARP and survi-
vin antibodies were purchased from Cell Signaling Tech-
nology (Danvers, MA). Monoclonal b-actin antibody was
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mined with whole cell lysates essentially as described
[20-23].
Northern blot analysis
For miRNA analysis, 20 μg total RNA per lane was elec-
trophoresed on 15% TBE urea polyacrylaminde gel (Invi-
trogen), electrophoretically transferred in 0.5 × TBE at 300
mÅ for 45 min to GeneScreen Plus membrane (PerkinEl-
mer, Boston, MA), UV cross-linked and hybridized in
ULTRAhyb-Oligo hybridization buffer (Ambion, Austin,
T X )a t4 2 ° Cw i t h
32P end-labeled DNA oligonucleotides
complementary to miR-27a. Blots were washed at 42°C in
2X SSC and 0.5% SDS for 30 min with gentle agitation.
Semiquantitative reverse transcription and real time PCR
RKO and SW480 colon cancer cells were treated with BA
at different concentrations for 24 h. Total RNA was
extracted using RNeasy Mini Kit (Qiagen), and 2 μgo f
RNA was used to synthesize cDNA using Reverse Tran-
scription System (Promega). Primers were obtained from
IDT and used for amplification were as follows: ZBTB10
(sense 5’-GCT GGA TAG TAG TTA TGT TGC-3’; anti-
sense 5’-CTG AGT GGT TTG ATG GAC AGA G-3’).
PCR products were electrophoresed on 1% agarose gels
containing ethidium bromide and visualized under UV
transillumination. Real time PCR for determining miR-
27a, ZBTB10 and Myt-1 RNA levels were determined
essentially as described [20-23].
Reactive oxygen species (ROS) and mitochondrial
membrane potential assays
Cellular ROS levels were evaluated with the cell permeant
probe CM-H2DCFDA (5-(and-6)-chloromethyl-2’7’-
dichlorodihydrofluorescein diacetate acetyl ester) from
Invitrogen. Following 36 h treatment, cells plated on a 6-
well cell culture plate were loaded with 10 μMC M -
H2DCFDA for 1 h, washed once with serum-free medium,
and analyzed for ROS levels using Beckman Coulter XL
four-color cytometer. Each experiment was done in tripli-
cate and results are expressed as mean ± S.E. for each
treatment group. Mitochondrial membrane potential
(MMP) was measured with Mitochondrial Membrane
Potential Detection Kit (Stratagene) according to the man-
ufacturer’sp r o t o c o lu s i n gJ C - 1d ye, and mitochondrial
membrane potential shift was measured using FACS Cali-
bur flow cytometer using CellQuest acquisition software
(BD Biosciences). J-aggregates were detected as red fluores-
cence and J-monomers are detected as green fluorescence.
Xenograft studies in athymic mice
Female athymic nude mice were purchased from Harlan
Laboratories (Indianapolis, IN) and were cared for and
used in accordance with institutional guidelines. To
produce tumors, RKO cells (5 × 10
6; ≥ 90% viable) were
subcutaneously injected into the flanks of individual
mice. Tumors were allowed to grow for 6 days until
palpable and mice were then randomized into two
groups (6 mice/group) and dosed by oral gavage with
corn oil or BA (25 mg/kg/day) every second day for 22
days. The mice were weighed, and tumor size was mea-
sured every second day with calipers to permit calcula-
tion of tumor volumes: V = LW
2/2, where L and W
were length and width, respectively. After BA treatment,
the animals were sacrificed; final body and tumor
weights were determined, and major visceral organs
were collected and lysates were used for western blot
analysis of Sp proteins.
Results
1. BA inhibits colon cancer cell growth and induces
apoptosis
BA inhibits growth of multiple cancer cell lines [39,40],
and results in Figure 1A demonstrate that BA inhibited
RKO and SW480 cell proliferation after treatment for 48
or 96 h. Growth inhibition was observed at concentrations
of ≥ 5 μM in both cell lines at the two time points. The
effects of BA on distribution of cells in G0/G1,Sa n dG 2/
M phases of the cell cycle was cell context-dependent (Fig-
ures 1B and 1C). In RKO cells, BA dramatically decreased
the percentage of cells in G0/G1 and S phase and increased
the percent in G2/M, whereas in SW480 cells, there was a
slight decrease in G0/G1 and S phase and a parallel
increase in the percentage of cells in G2/M. Treatment of
RKO and SW480 cells with BA also enhanced PARP clea-
vage (Figure 1D) which is consistent with induction of
apoptosis in these cell lines; however, after treatment of
the cells for only 24 hr, < 10% of the cells were sub-G1 in
FACS analysis.
2. BA decreases expression of Sp1, Sp3, Sp4 and Sp-
regulated gene products in colon cancer cells
Previous studies showed that BA decreases Sp1, Sp3 and
Sp4 protein expression in prostate and bladder cancer
cells [20,32], and results in Figure 2A confirm that similar
effects were observed in RKO and SW480 cells. These
results were similar to that observed for CDODA-Me
and GT-094 in these cell lines [38,40]. Moreover, BA also
induced cleaved PARP and decreased expression of survi-
vin, an inhibitor of apoptosis in RKO and SW480 cells,
and VEGF (Figure 2B). These results are consistent with
previous studies showing that both survivin and VEGF
are Sp-regulated genes [20,29]. RNA interference studies
which knockdown Sp1, Sp3 and Sp4 (individually or
combined) have identified EGFR, p65 subunit of NFB,
PTTG1 and cyclin D1 as Sp-regulated genes [32-35], and
results in Figure 2C show that BA decreased expression
of their corresponding gene products in RKO and
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Page 3 of 12Figure 1 BA inhibits growth and induces apoptosis in colon cancer cells. (A) Inhibition of cell proliferation. Cells were treated with BA for
48 or 96 h and then counted as described in the Materials and Methods. Cell cycle progression in RKO (B) and SW480 (C) cells. Cells were
treated with DMSO (0), 10 or 15 μM BA for 24 h and analyzed by FACS analysis as described in the Materials and Methods. (D) Induction of
PARP cleavage. RKO and SW480 cells were treated with BA for 24 h and whole cell lysates were analyzed for cleaved PARP as described in the
Materials and Methods. Results in (A) - (C) are expressed as means ± SE for at least 3 replicate experiments and significant (p < 0.05) differences
from controls (0, DMSO) are indicated (*).
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Page 4 of 12Figure 2 BA decreases Sp proteins and Sp-regulated genes. BA decreases Sp proteins in RKO and SW480 cells (A) and Sp-regulated genes
(B). Cells were treated with DMSO (0) or BA for the indicated times and whole cell lysates were analyzed by western blots as described in the
Materials and Methods. (C) BA and Sp1/Sp3/Sp4 (iSp) knockdown decrease Sp-regulated genes. Cells were either treated with BA or transfected
with iSp and whole cell lysates were analyzed by western blots as described in the Materials and Methods. (D) Effects of proteasome inhibitors.
Cells were treated with BA ± proteasome inhibitors MG132 or lactacystin for 24 h and whole cell lysates were analyzed by western blots as
described in the Materials and Methods.
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Sp3 and Sp4 using an oligonucleotide cocktail (iSp)
[20,21,32-34] also decreased expression of p65, PTTG-1,
EGFR and cyclin D1 in RKO cells (Figure 2C) confirming
their regulation by Sp transcription factors in colon can-
cer cells.
Treatment of RKO cells with the proteasome inhibitor
MG132 alone was cytotoxic; however, in RKO cells trea-
ted with BA or the proteasome inhibitor lactacystin
alone or in combination, BA-induced downregulation of
S p 1 ,S p 3 ,a n dS p 4w a sn o ti n h i b i t e di n d i c a t i n gt h a tt h e
effects were proteasome-independent (Figure 2D).
MG132 was not toxic to SW480 cells and BA-induced
downregulation of Sp1, Sp3a n dS p 4w a sr e v e r s e di n
cells cotreated with BA plus MG132 (and lactacystin;
data not shown), demonstrating a proteasome-depen-
dent pathway in this cell line as previously observed in
LNCaP cells treated with BA [20].
3. BA decreases Sp and Sp regulated gene expression in
RKO cells through disruption of miR-27a:ZBTB10
We further investigated BA-mediated repression of Sp and
Sp-regulated genes in RKO cells by determining the effects
of BA on a series of GC-rich constructs containing promo-
ter inserts from the Sp1, Sp3, VEGF, survivin and PTTG-1
which are downregulated after loss of Sp proteins
[18-21,29,30]. Results in Figures 3A and 3B show that BA
decreased luciferase activity in RKO cells transfected with
pSp1-FOR4-luc, pSp1-FOR2-luc, pSp3-FOR5-luc and
pSp3-FOR2-luc constructs which contain the GC-rich
-751 to -20 and -281 to -20 region of the Sp1 gene promo-
ter and the GC-rich -417 to -38 and -213 to -38 regions of
the Sp3 promoter, respectively [36]. BA also decreased
luciferase activity in RKO cells transfected constructs con-
taining VEGF (-2018 to +5), survivin (-259 to +49), and
PTTG-1 (-1373 to +3) promoter inserts (Figure 3C), and
these results are also consistent with previous studies
using agents or RNA interference that downregulate Sp
protein expression [19,20,30].
ROS and hydrogen peroxide (H2O2)p l a yar o l ei n
downregulation of Sp1, Sp3 and Sp4 in pancreatic and
bladder cancer cells [34,37] and treatment of RKO cells
with BA for 36 h induced ROS as determined by FACS
analysis using the fluorescent ROS scavenger H2DCFDA
(Figure 4A). Moreover, in cells treated with BA plus cata-
lase, there was a decrease in fluorescence indicating that
catalase inhibited ROS formation. Treatment of RKO
cells with BA decreased expression of Sp1, Sp3 and Sp4
proteins and this effect was partially reversed in RKO
cells cotreated with BA plus catalase (Figure 4B). BA-
decreased MMP was indicated by increased green/red
fluorescence associated with the JC-1 monomer and
aggregates, respectively; moreover, BA-induced growth
inhibition was also reversed in RKO cells cotreated with
BA plus catalase (Figure 4C), thus confirming an impor-
tant role for ROS (H2O2) in mediating the growth inhibi-
tory effects of BA.
Previous studies show that ROS-dependent disruption
of miR-27a:ZBTB10 is important for Sp downregulation
[33,38] and Figure 5A shows that BA decreased miR-
27a, as determined by Northern blot analysis, and semi-
quantitative RT-PCR confirmed induction of ZBTB10.
Moreover, downregulation of miR-27a was also paral-
leled by decreased luciferase activity in RKO cells trans-
fected with a construct (pmiR-27a-luc) containing the
-639 to +36 region of the promoter for the miR-23a-
miR-27a-miR-24-2 [41] cluster (Figure 5B). Using real
time PCR, BA significantly decreased miR-27a and
induced ZBTB10 (Figure 5C) expression and these
responses were all significantly attenuated in RKO cells
cotreated with BA plus catalase. These results confirm
that BA-induced suppression of Sp1, Sp3 and Sp4 is
linked to induction of ROS and ROS-mediated disrup-
tion of miR-27a:ZBTB10. The Myt-1 gene is associated
with G2/M arrest and is repressed by miR-27a in colon
and breast cancer cells [22,36]. BA induced Myt-1
mRNA in RKO cells; this response was also attenuated
in cells cotreated with BA plus catalase (Figure 5D) and
this was consistent with ROS-mediated regulation of
miR-27a and ZBTB10 (Figure 5C).
4. BA inhibits colon tumor growth
Athymic nude mice bearing RKO cells as xenografts were
treated with corn oil (control) or BA (25 mg/kg/d).
Treatment with BA significantly decreased tumor growth
and volume and this was accompanied by decreased
tumor weights measured after sacrifice (Figures 6A and
6B). Lysates from control and BA-treated tumors were
analyzed by western blot analysis for Sp1, Sp3 and Sp4
protein expression, and quantitated (relative to b-actin).
The results showed that BA significantly decreased
expression of Sp1, Sp3 and Sp4 (Figure 6C) and these
results were consistent with comparable effects observed
in vitro (Figure 2A).
Discussion
The anticancer activity of BA initially showed high
potency against melanoma in cell culture and animal
models, and subsequent studies show the effectiveness of
this compound against multiple tumor types [39,40,42].
The low in vivo toxicity of BA coupled with supporting
in vitro and in vivo results suggest that this compound or
some derivative has potential for clinical applications in
cancer chemotherapy. However, BA is a highly lipophilic
molecule with limited water solubility and this may
decrease in vivo uptake of this compound; therefore,
development of specialized formulations/carriers such as
liposomes may help to enhance the in vivo efficacy of BA
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laboratory showed that BA inhibits prostate cancer cell
and tumor growth and this is accompanied by protea-
some-dependent degradation of Sp1, Sp3 and Sp4 and
several Sp-regulated pro-oncogenic gene products [20].
Several other anticancer agents including tolfenamic acid,
curcumin, arsenic trioxide, a nitro-NSAID (GT-094), and
two synthetic triterpenoid derivatives, CDDO-Me and
CDODA-Me, also induce Sp downregulation in various
cancer cell lines via proteasome-dependent and -inde-
pendent pathways [19,21,33-38].
BA inhibits colon cancer cell growth and induces cas-
pase-dependent PARP cleavage in RKO and SW480
colon cancer cells (Figure 1) and these results are con-
sistent with other reports on the effects of BA on colon
cancer cell lines [39,40,44-46]. Moreover, BA also inhib-
ited tumor growth in athymic nude mice bearing RKO
cells as xenografts (Figure 6). We observed that BA
Figure 3 BA inhibits luciferase activity in RKO cells transfected with GC-rich constructs. Transfection with constructs containing Sp1 (A),
Sp3 (B) and Sp-regulated (C) gene promoter constructs. RKO cells were transfected with the indicated constructs, treated with DMSO or BA, and
luciferase activity (normalized to b-galactosidase) was determined as described in the Materials and Methods. Results are expressed as means ±
SE for at least 3 replicated determinations as significant (p < 0.05) is indicated (*).
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both RKO and SW480 colon cancer cells and tumors
(Figures 2A and 6C) and this was accompanied by paral-
lel decreases in survivin and VEGF (Figures 2A and 2B),
and these results are comparable to those observed in
LNCaP prostate and KU7 bladder cancer cells treated
with BA [20,32]. Recent RNA interference studies show
that p65 (NFB subunit), EGFR, cyclin D1, and pituitary
tumor transforming gene-1 (PTTG-1) are also Sp-regu-
lated genes [32-35], and results in Figure 3C demon-
strate that BA decreased expression of these gene
products in RKO and SW480 cells. Moreover, knock-
down of Sp1, Sp3 and Sp4 (in combination) in RKO
colon cancer cells also decreased expression of EGFR,
cyclin D1, p65 and PTTG-1, confirming the role of Sp
transcription factors in regulating expression of these
Figure 4 BA decreases MMP and induces ROS in RKO cells. (A) Induction of ROS. RKO cells were treated with 15 μM BA, catalase or BA plus
catalase for 36 h and ROS production was determined using the fluorescent probe H2DCFDA as described in the Materials and Methods. Role
of ROS in BA-induced Sp downregulation (B) and growth inhibition and BA effects on MMP (C). Cells were treated with DMSO (control), BA,
catalase or BA plus catalase and Sp proteins (in whole cell lysates), MMP and cell growth were determined as described in the Materials and
Methods. Results (C) are expressed as means ± SE for 3 replicate experiments and significant (p < 0.05) growth inhibition by BA (*) and rescue
by catalase (**) are indicated. BA-induced inhibition of MMP was not affected by cotreatment with catalase (data not shown).
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apoptosis by BA since many of these Sp-regulated genes
are important for survival pathways.
Previous studies showed that BA-induced downregula-
tion of Sp1, Sp3 and Sp4 was proteasome-dependent in
LNCaP cells but proteasome-independent in KU7
Figure 5 Role of miR-27a in regulation of BA-mediated responses. (A) Repression of miR-27a and induction of ZBTB10. RKO cells were
treated with DMSO or BA and miR-27a and ZBTB10 expression were determined by Northern blot and semi-quantitative RT-PCR, respectively, as
described in the Materials and Methods. (B) BA decreases miR-27a promoter activity. RKO cells were transfected with pMiR-27a(-639/+36)-luc,
treated with DMSO or BA and luciferase activity determined as described in the Materials and Methods. Role of BA-induced ROS on expression
of miR-27a and ZBTB10 (C) and Myt-1 (D). RKO cells were treated with DMSO, BA, catalase or BA plus catalase for 36 h and miR-27a, ZBTB10 and
Myt1 mRNA levels were determined by real time PCR as described in the Materials and Methods. Results in (B) - (D) are expressed as means ±
SE for at least 3 replicate determinations and significant (p < 0.05) effects by BA (*) and reversal by catalase (**) are indicated.
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observed in RKO and SW480 colon cancer cells (Figure
2D) where BA-induced downregulation of Sp proteins
was proteasome-independent and -dependent, respec-
tively. This demonstrates that, for BA and possibly other
drugs that downregulate Sp1, Sp3, Sp4 and Sp-regulated
genes, the pathways required for this response are vari-
able and dependent not only on tumor type but also cell
context within the same tumor. At least two of these
pathways, namely induction of proteasome- and cas-
pase-dependent degradation of Sp proteins, involve acti-
vation of post-transcriptional processes [20,21,37];
however, their mechanisms have not been determined
and are currently being investigated in this laboratory.
We have previously reported that the synthetic triter-
penoid CDODA-Me and the NO-NSAID GT-094
decrease Sp protein expression in SW480 and RKO
colon cancer cells through a transcriptional repression
pathway in which miR-27a is decreased and this results
i nt h ei n d u c t i o no fZ B T B 1 0 ,at r a n s c r i p t i o n a lr e p r e s s o r
[36,38]. BA decreased luciferase activity in RKO cells
transfected with constructs containing several GC-rich
promoter inserts (Figures 3B-D) and also decreased
expression of miR-27a and induced expression of
Figure 6 BA inhibits colon tumor growth in vivo. Inhibition of tumor growth (A) and weights (B). BA (25 mg/kg/d) was administered (orally)
to athymic nude mice every second day and tumor volumes and weights were determined as described in the Materials and Methods. (C)
Downregulation of Sp1, Sp3 and Sp4. Tumor lysates from individual mice were analyzed by western blots as described in the Materials and
Methods and Sp1, Sp3 and Sp4 protein levels were normalized to b-actin. Results in (A) - (C) are means ± SE for at least 8 mice in the control
(corn oil) and BA-treated groups and significant (p < 0.05) inhibition by BA is indicated (*).
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sion of ZBTB10 and antisense-miR-27a also decreases
expression of Sp1, Sp3, Sp4 and Sp-regulated genes in
colon cancer cells [36], the mechanism of action of BA
in RKO cells is linked to disruption of miR-27a:ZBTB10
as previously reported for CDODA-Me and GT-094 in
colon cancer cells [36,38].
BA is known to be a mitochondriotoxic drug and
decreases the mitochondrial membrane potential in sev-
eral different cancer cell lines leading to induction of
apoptosis [39,40,44] and BA also decreased MMP in
RKO cells (Figure 4C). Previous studies have demon-
s t r a t e dt h a ta tl e a s tf o u ra g e n t st h a ta r em i t o c h o n d r i o -
toxic and induce ROS also downregulate Sp proteins; this
effect is ROS-dependent and reversible with antioxidants
or catalase, and compounds activating this pathway
include arsenic trioxide (bladder), curcumin and CDDO-
Me (pancreatic), and GT-094 (colon) [33,37,38]. More-
over, for GT-094 and CDDO-Me, the mechanism of
ROS-dependent downregulation of Sp1, Sp3, and Sp4
involves disruption of miR-27a:ZBTB10 [33,38]. Results
of this study show that BA also induced ROS-downregu-
lated Sp1, Sp3, Sp4 and miR-27a and induced ZBTB10 in
RKO cells, and all of these responses were significantly
attenuated in cells cotreated with BA plus catalase (Fig-
ure 4). Moreover, catalase also reversed the growth inhi-
bitory effects of BA (Figure 4C), further demonstrating
the importance of ROS activation for the anticancer
activity of this compound in RKO cells. In contrast to
previous studies showing that CDODA-Me and GT-094
activated transcriptional repression of Sp proteins in
both RKO and SW480 cells [33,36], BA induced tran-
scriptional repression in RKO cells but activated the pro-
teasome pathway for degradation of Sp proteins in
SW480 cells. The mitochondrial or extra-mitochondrial
origins of ROS in cancer cells treated with BA and other
agents that downregulate Sp transcription factors is cur-
rently being investigated.
Conclusions
In summary, we have shown that the anticancer activity
of BA in colon cancer cells is due, in part, to downregu-
lation of Sp1, Sp3, Sp4 and Sp-regulated prooncogenic
gene products. The upstream mechanisms associated
with decreased expression of Sp1, Sp3 and Sp4 are cell
context-dependent and involves proteasome-dependent
(SW480) and proteasome-independent (RKO) pathways.
T h er e s p o n s ei nR K Oc e l l si n v o l v e sl o s so fM M Pa n d
induction of ROS as previously reported for BA in other
studies [39,40] and this is coupled with ROS-dependent
disruption of miR-27a:ZBTB10. BA also decreased luci-
ferase activity in RKO cells transfected with a construct
containing the -639 to +39 region of the miR-27a pro-
moter, and we are currently examining the mechanisms
associated with ROS-dependent effects on critical tran-
scription factors interacting with the promoter and also
the functional significance of ROS-dependent downregu-
lation of miR-23a and miR-24-2 which form part of the
miR-23a-miR-27a-miR24-2 cluster. These results
coupled with several recent reports demonstrate poten-
tial clinical applications for BA and related compounds
alone or in combination with other anticancer agents
[47-49].
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